Berberis aristata (Indian Barberry)

Berberis aristata (Indian Barberry)

Product Name: Барбарис лекарственный, Berberis aristata, Arznei-Berberitze, Agracejo indio, Épine-vinette médicinale, البرباريس الطبي, พันช์อินเดีย, Hind berberisi, Дарыя карагана, Hind berberisi, Барбарис доруӣ, Vaistinė raugerškis, Ārstniecības bārbeles, Барбарис лікарський, Hind berberisi, ברבריס רפואי

Synonyms: барбарис индийский, барбарис остроконечный, барбарис длиннокорневищный, индийский барбарис; Indian barberry, Tree turmeric; Indische Berberitze, Gelber Holzstamm; Agracejo amarillo, Berberis india; Épine-vinette jaune, Curcuma en arbre; برباريس هندي, الكركم الهندي; พันช์อินเดีย, ต้นขมิ้นแขก

Main Indications for Use of Berberis aristata: Intestinal amebiasis, bacterial dysentery, salmonellosis, gastritis with increased secretion, duodenitis, gastric ulcer, duodenal ulcer, cholecystitis, cholangitis, viral hepatitis B, viral hepatitis C, liver cirrhosis, cutaneous leishmaniasis, candidiasis of mucous membranes, bacterial vaginosis, urogenital chlamydia, chronic bacterial prostatitis, glaucoma, diabetic retinopathy, bronchiectasis, arterial hypertension, premenstrual syndrome, acute myeloid leukemia, colorectal cancer, hepatocellular carcinoma.

Use of Berberis aristata in Mixtures and Complexes: Chronic pancreatitis, ulcerative colitis, Crohn's disease, hepatic steatosis, osteoarthritis, rheumatoid arthritis, type 2 diabetes mellitus, neurodermatitis, psoriasis, microbial eczema, cancer-associated fatigue, chronic heart failure of I–II functional class, smoker's chronic bronchitis, human immunodeficiency virus, persistent herpes infection, ovarian cancer, breast cancer.

Pharmacological Properties of Berberis aristata: antioxidant, hepatoprotective, antimicrobial, antifungal, antiparasitic, anti-inflammatory, choleretic, antidiarrheal, spasmolytic, anti-glaucoma, hypotensive, antitumor, hypoglycemic, immunomodulating, antinociceptive, neuroprotective, anti-angiogenic, antiproliferative, pro-apoptotic.

Dosage of Pharmaceutical Forms — Berberis aristata

Powder — Berberis aristata

Indications (Powder): Intestinal amebiasis, bacterial dysentery, salmonellosis, gastritis with increased secretion, duodenitis, gastric ulcer, duodenal ulcer, cholecystitis, cholangitis, viral hepatitis B, viral hepatitis C, liver cirrhosis, candidiasis of mucous membranes, bacterial vaginosis, urogenital chlamydia, chronic bacterial prostatitis, premenstrual syndrome, colorectal cancer, hepatocellular carcinoma.

Standard Dosage (Powder): 1.5 grams of powder 2 times a day 20 minutes before meals, with warm water at a temperature of 35–40 °C. Course — 14 days.

Enhanced Dosage (Powder): 2.5 grams of powder 3 times a day for gastric ulcer, viral hepatitis B and C, and colorectal cancer as part of adjuvant therapy. Course duration — 21 days.

Maximum Dosage (Powder): 3 grams of powder 3 times a day for active forms of amebiasis, leishmaniasis, bacterial cholangitis, and hepatocellular carcinoma (as part of multicomponent therapy). No more than 10 days.

Preventive Dosage (Powder): 1 gram once a day 30 minutes before meals for chronic gastritis, biliary dyskinesia, hepatic steatosis, and metabolic syndrome. Frequency — 14 days of intake, 14 days of break, up to 3 months.

Pediatric Dosage (Powder): Use is permitted from 12 years of age with a body weight of at least 35 kilograms. Dosage — 0.5 grams 2 times a day. For children under 12 years or with a weight of less than 35 kilograms — use is not recommended due to the lack of reliable safety data.

Contraindications (Powder): Acute pancreatitis, biliary obstruction, hepatic function decompensation, pregnancy, lactation. Data on contraindications in children under 12 years are absent.

Side Effects (Powder): In case of overdose, dyspeptic disorders (nausea, bitter taste in the mouth), diarrhea, spastic pain in the right hypochondrium, and increased gastric secretion are possible.

Adjustment for Patient Body Weight: For body weight below 60 kilograms — reduce the daily dose by 20%. For body weight above 90 kilograms — an increase in dose by 20% is possible, with tolerability and absence of side effects.

Preparation Method (Powder): Raw material: cleaned and dried roots of Berberis aristata — 105 grams. The roots are cleaned of external impurities, washed with running water, and dried at a temperature not exceeding 40 °C to a residual moisture of 8–10%. Then ground to a powder state with a fraction of no more than 0.3 millimeters. The resulting powder is sifted and packaged in airtight jars. Additives and stabilizers are not used. To impart a slight oiliness, the addition of 1 gram of organic coconut oil per 100 grams of powder before packaging is possible (optional, according to Ayurvedic tradition).

Storage Conditions and Shelf Life (Powder): Store in a tightly closed glass or ceramic container, in a dark, dry place at a temperature of 10 to 25 °C. Avoid exposure to direct light, moisture, and electromagnetic fields. Shelf life — 12 months. After opening — use within 45 days.

Dry Extract — Berberis aristata

Indications (Dry Extract): Intestinal amebiasis, bacterial dysentery, gastritis with increased secretion, gastric ulcer, duodenal ulcer, chronic cholecystitis, viral hepatitis B, viral hepatitis C, liver cirrhosis, candidiasis of mucous membranes, bacterial vaginosis, urogenital chlamydia, colorectal cancer, hepatocellular carcinoma, acute myeloid leukemia.

Standard Dosage (Dry Extract): 300 milligrams of dry extract 2 times a day 15 minutes before meals, with warm water at a temperature of 35–40 °C. Course — 10–14 days.

Enhanced Dosage (Dry Extract): 500 milligrams 3 times a day for viral hepatitis, colorectal cancer, and ulcerative disease with pain syndrome. Course duration — 21 days.

Maximum Dosage (Dry Extract): 750 milligrams 3 times a day for cutaneous leishmaniasis, systemic mycoses, hepatocellular carcinoma, and acute forms of parasitic infections. Used for no more than 7 days, strictly under medical supervision.

Preventive Dosage (Dry Extract): 150 milligrams once a day for chronic gastritis, biliary dyskinesia, non-alcoholic fatty liver disease, and metabolic syndrome. Intake — 14 days, break — 14 days, up to 3 cycles per year.

Pediatric Dosage (Dry Extract): From 12 years of age with a body weight of at least 35 kilograms — 150 milligrams 1–2 times a day. In children under 12 years, safety and efficacy have not been scientifically confirmed.

Contraindications (Dry Extract): Pregnancy, lactation, severe forms of liver failure, biliary obstruction. Scientific data on contraindications in children under 12 years are absent.

Side Effects (Dry Extract): Nausea, headache, increased intestinal motility, and bitter taste in the mouth may be observed. When exceeding the dosage — dyspepsia, spastic pain, irritation of the gastrointestinal mucosa.

Adjustment for Patient Body Weight: For patients with body weight below 60 kilograms — the dosage is reduced by 25%. For patients with body weight above 90 kilograms — correction with an increase in dose by 20% is possible in the absence of side reactions.

Preparation Method (Dry Extract): Raw material: dried and ground root of Berberis aristata — 500 grams. Carry out water-alcohol extraction using 70% ethanol in a ratio of 1:5. Infuse at a temperature of 60 °C for 6 hours. Evaporate under vacuum to 1/5 of the volume. Subject the resulting mass to spray drying at a temperature of 45–50 °C. For stabilization, the addition of 5 grams of organic maltodextrin is allowed. Yield — about 100 grams of dry extract.

Storage Conditions and Shelf Life (Dry Extract): Store in a dry place protected from light and electromagnetic radiation at a temperature of 10 to 25 °C, in an airtight container. After opening, use within 60 days. Total shelf life — 18 months.

Tincture — Berberis aristata

Indications (Tincture): Intestinal amebiasis, salmonellosis, gastritis with increased secretion, gastric ulcer, duodenal ulcer, chronic cholecystitis, viral hepatitis B, viral hepatitis C, candidiasis of mucous membranes, bacterial vaginosis, colorectal cancer, hepatocellular carcinoma.

Standard Dosage (Tincture): 20 drops of tincture in 50 milliliters of water 2 times a day 20 minutes before meals. Course — 10 days, repeat possible after a 5-day break.

Enhanced Dosage (Tincture): 30 drops of tincture 3 times a day for viral hepatitis, colorectal cancer during chemotherapy, and spastic conditions of the gallbladder. Course — 14 days.

Maximum Dosage (Tincture): 40 drops 3 times a day for no more than 5 days for active forms of amebiasis, severe forms of bacterial dysentery, and cholangitis. Permissible only under medical supervision.

Preventive Dosage (Tincture): 10 drops of tincture in 50 milliliters of water once a day in the morning, for chronic gastritis, cholestasis, and metabolic syndrome in persons over 50 years. Preventive course — 10 days of intake, then a 20-day break. Repeated up to 3 times a year.

Pediatric Dosage (Tincture): Use is possible from 14 years of age with a body weight of at least 45 kilograms. Dosage — 10 drops once a day diluted with water. Safety in children under 14 years has not been scientifically established.

Contraindications (Tincture): Acute hepatitis with liver failure, choledocholithiasis, alcohol dependence, epilepsy. Contraindicated during pregnancy and lactation. Scientifically confirmed safety data in children under 14 years are absent.

Side Effects (Tincture): In case of overdose, headache, nausea, palpitations, increased intestinal peristalsis, and bitter taste in the mouth are possible.

Adjustment for Patient Body Weight: For patients with body weight less than 60 kilograms, it is recommended to reduce the dosage by 20%. For patients with body weight more than 90 kilograms — an increase in dose by 15–20% with good tolerability.

Preparation Method (Tincture): Raw material: root of Berberis aristata — 30 grams, 70% ethyl alcohol — 100 milliliters. Thoroughly grind the roots to a fraction of 1–2 millimeters. Place in a glass container, pour with alcohol, seal tightly. Infuse in a dark, cool place at a temperature of 20–25 °C for 14 days with daily shaking. After infusion, filter through gauze or a paper filter, store in a tightly closed dark glass container. Yield — about 95 milliliters of finished tincture.

Storage Conditions and Shelf Life (Tincture): Store in an airtight dark glass container at a temperature of 10 to 25 °C, in a place protected from light and electromagnetic radiation. Avoid heating, proximity to electrical appliances, and open fire. Shelf life — 24 months. After opening, use within 60 days.

Oil Infusion — Berberis aristata

Indications (Oil Infusion): Chronic bacterial prostatitis, urogenital chlamydia, bacterial vaginosis, vulvar candidiasis, atrophic vaginitis, anal itching, inflammatory external hemorrhoids, perirectal dermatitis, prostate cancer as part of supportive therapy.

Standard Dosage (Oil Infusion): 5 milliliters of infusion rectally or vaginally once a day before bedtime, after hygienic treatment. Externally — 3 milliliters 2 times a day on the inflamed area. Course — 10–14 days.

Enhanced Dosage (Oil Infusion): 5 milliliters 2 times a day (morning and evening) locally or intravaginally/rectally for acute forms of bacterial vaginosis, candidiasis, and prostatitis. Course duration — 21 days.

Maximum Dosage (Oil Infusion): Up to 10 milliliters per day (locally and internally combined) for 5–7 days for acute inflammation or malignant neoplasms as part of adjuvant therapy. Not allowed without medical supervision.

Preventive Dosage (Oil Infusion): 3 milliliters externally or 5 milliliters rectally/vaginally once a day before bedtime for chronic inflammatory conditions of the urogenital tract, postmenopause, and chronic prostatitis in remission. Course — 10 days, repeat every 2 months.

Pediatric Dosage (Oil Infusion): Safety data for use in children and adolescents are absent. Use is not recommended under 18 years.

Contraindications (Oil Infusion): Acute proctitis, bleeding hemorrhoids, allergy to barberry or coconut oil, vaginal bleeding of unclear etiology. Safety data during pregnancy and lactation are absent; use is not recommended without medical consultation.

Side Effects (Oil Infusion): Local burning, hyperemia, increased vaginal or anal secretion. In case of overdose — mucosal irritation, contact dermatitis.

Adjustment for Patient Body Weight: Correction is not required since it is applied locally. In case of increased skin sensitivity and body weight below 50 kilograms, a reduction in dosage to 2–3 milliliters per day is possible.

Preparation Method (Oil Infusion): Raw material: root of Berberis aristata — 20 grams, organic cold-pressed coconut oil — 100 grams. Grind the root to 1–2 millimeters, place in a glass heat-resistant vessel, pour with oil. Infuse in a water bath at a temperature of 50–55 °C for 4 hours. Cool, strain through gauze. Store in a dark glass container. Yield — about 95 grams of finished infusion.

Storage Conditions and Shelf Life (Oil Infusion): Store in a dark, cool place at a temperature of 8–20 °C, in an airtight dark glass container, protected from light and electromagnetic radiation. Shelf life — up to 6 months. After opening, use within 30 days.

Vaginal Suppositories — Berberis aristata

Indications (Vaginal Suppositories): Bacterial vaginosis, vulvar and vaginal candidiasis, urogenital chlamydia, atrophic vaginitis, bacterial cervicitis, vaginitis of mixed etiology, chronic adnexitis, cervical cancer during chemoradiotherapy (as part of an adjuvant regimen).

Standard Dosage (Vaginal Suppositories): 1 suppository (containing 300 milligrams of dry extract) once a day at night, intravaginally, after hygienic treatment. Course — 10 days.

Enhanced Dosage (Vaginal Suppositories): 1 suppository 2 times a day (morning and evening) for urogenital chlamydia, candidiasis, and vaginosis with pronounced inflammation and purulent discharge. Duration — up to 14 days.

Maximum Dosage (Vaginal Suppositories): Up to 3 suppositories per day (every 8 hours) is possible short-term (3–5 days) for severe forms of vaginitis, recurrent candidiasis, and concomitant oncological process in the cervical area. Only under medical supervision.

Preventive Dosage (Vaginal Suppositories): 1 suppository once a day before bedtime for 7 days for recurrent forms of bacterial vaginosis, fungal superinfection, and postmenopausal atrophic vaginitis. Repeat — no more than one course every 2 months.

Pediatric Dosage (Vaginal Suppositories): Use in persons under 18 years is not recommended. Clinical safety studies in pediatrics and pubertal age are absent.

Contraindications (Vaginal Suppositories): Bleeding from the genital tract of unknown origin, pregnancy, individual intolerance to components. Data on use during lactation are absent and not scientifically registered.

Side Effects (Vaginal Suppositories): Burning in the vagina, increased mucous discharge, local mucosal hyperemia. In case of overdose — contact vaginitis, mucosal irritation, increased inflammation symptoms.

Adjustment for Patient Body Weight: Correction is not required. For body weight less than 50 kilograms, the use of suppositories with a dose of 150–200 milligrams of extract is possible. Standard dose — for women with body weight from 50 to 90 kilograms.

Preparation Method (Vaginal Suppositories): For 100 grams of suppositories: dry extract of barberry root — 3 grams, organic coconut oil — 80 grams, beeswax — 17 grams. Melt coconut oil in a water bath (temperature not exceeding 45 °C), add the dry extract and mix thoroughly until homogeneous. Add grated beeswax, stir until completely dissolved. Pour into suppository molds of 2 grams each and cool at a temperature of 4 °C until solidified. Store in the refrigerator.

Storage Conditions and Shelf Life (Vaginal Suppositories): Store in a cool place at a temperature of 4–8 °C, in the original packaging, protected from light and electromagnetic radiation. Shelf life — up to 6 months. After opening the package, use within 10 days.

Rectal Suppositories — Berberis aristata

Indications (Rectal Suppositories): Chronic bacterial prostatitis, chronic proctitis, inflammatory external hemorrhoids, anal itching, perirectal dermatitis, anal fissure, rectal cancer during chemotherapy, hepatocellular carcinoma as part of a supportive regimen.

Standard Dosage (Rectal Suppositories): 1 suppository (containing 300 milligrams of dry extract) once a day at night, after preliminary bowel evacuation. Course — 10 days.

Enhanced Dosage (Rectal Suppositories): 1 suppository 2 times a day (morning and evening) for pronounced inflammation in the rectal area, exacerbation of chronic bacterial prostatitis, and recurrent hemorrhoids. Duration — up to 14 days.

Maximum Dosage (Rectal Suppositories): Up to 3 suppositories per day is possible short-term (3–5 days) for acute inflammatory conditions and rectal cancer as part of a multicomponent regimen. Use only under specialist supervision.

Preventive Dosage (Rectal Suppositories): 1 suppository every other day, course — 10 applications. Recommended for chronic prostatitis, after surgical treatment of hemorrhoids, and for frequent exacerbations of perirectal dermatitis. Repeat course — after 60 days.

Pediatric Dosage (Rectal Suppositories): Contraindicated under 14 years. Safety of use in pediatrics has not been scientifically confirmed.

Contraindications (Rectal Suppositories): Fresh rectal bleeding, acute paraproctitis, individual intolerance. Data on use during pregnancy and lactation are absent and not scientifically registered.

Side Effects (Rectal Suppositories): Local burning, sensation of a foreign body, frequent urge to defecate. In case of overdose — increased irritation of the rectal mucosa, local edema, false urges.

Adjustment for Patient Body Weight: For patients with body weight below 50 kilograms, it is recommended to use suppositories with a dose of 150–200 milligrams. For body weight above 90 kilograms, dose adjustment to 400 milligrams per suppository is possible with good tolerability.

Preparation Method (Rectal Suppositories): Composition per 100 grams: dry extract of barberry — 3 grams, cold-pressed coconut oil — 80 grams, beeswax — 17 grams. Heat coconut oil in a water bath to 45 °C, introduce the extract, mix thoroughly. Add wax and heat until completely dissolved. Pour into suppository molds of 2 grams each. Cool until solidified at 4 °C. Store in an airtight container.

Storage Conditions and Shelf Life (Rectal Suppositories): Store at a temperature of 4 to 8 °C, in a place protected from light and EMI. Shelf life — 6 months. After opening the package, use within 10 days.

Nasal Drops — Berberis aristata

Indications (Nasal Drops): Bacterial rhinitis, chronic rhinosinusitis, subacute sinusitis, nasal mucosal hypertrophy, chronic adenoiditis in adults, post-chemotherapeutic mucositis of the nasopharynx, nasal cavity inflammation in immunodeficiency states.

Standard Dosage (Nasal Drops): 2 drops in each nasal passage 2 times a day, morning and evening, after nasal hygiene. Course — 7–10 days.

Enhanced Dosage (Nasal Drops): 3 drops 3 times a day for pronounced bacterial rhinitis, purulent sinusitis, and post-radiation mucositis. Duration — up to 14 days.

Maximum Dosage (Nasal Drops): 4 drops in each nasal passage up to 4 times a day is possible for no more than 5 days for severe forms of bacterial sinusitis and chronic rhinosinusitis. Use beyond the specified period requires medical supervision.

Preventive Dosage (Nasal Drops): 1 drop in each nasal passage once a day in the morning for chronic rhinitis, mucosal hypertrophy, and during ARVI seasons in immunocompromised individuals. Preventive course — 10 days, repeat every 2 months.

Pediatric Dosage (Nasal Drops): Use is permitted from 12 years of age. 1 drop in each nasal passage 1–2 times a day. Safety in children under 12 years has not been scientifically confirmed.

Contraindications (Nasal Drops): Acute nasal bleeding, pronounced mucosal dryness, atrophic rhinitis, allergy to components. Data on use during pregnancy and lactation are absent and not scientifically registered.

Side Effects (Nasal Drops): Burning in the nose, sneezing, temporary hypersecretion. In case of overdose — mucosal edema, increased congestion, local headache.

Adjustment for Patient Body Weight: Dose adjustment is not required. For body weight below 45 kilograms, it is preferable to use the minimum dose (1 drop in each nostril).

Preparation Method (Nasal Drops): For 100 milliliters: dry extract of barberry — 1 gram, boiled water — 98 milliliters, vegetable glycerin — 1 milliliter. Dissolve the extract in water at a temperature of 40 °C, add glycerin. Filter through a 0.22 micron microfilters, pour into sterile dropper bottles. Optionally, 0.5 milliliters of organic coconut oil can be added if additional mucosal softening is required.

Storage Conditions and Shelf Life (Nasal Drops): Store in the refrigerator at a temperature of 4–8 °C, in a dark glass container. Shelf life — 30 days. After opening the bottle, use within 10 days, avoiding contact with the nasal mucosa.

Ear Drops — Berberis aristata

Indications (Ear Drops): Bacterial external otitis, subacute otitis media, eczema of the external auditory canal, pruritic form of external ear dermatitis, inflammation of the auditory canal due to bile outflow disorders, support for metastatic lesions of the temporal bone.

Standard Dosage (Ear Drops): 3 drops in each auditory canal 2 times a day, morning and evening. After instillation — lie on your side for 5 minutes. Course — 7 days.

Enhanced Dosage (Ear Drops): 4 drops 3 times a day for pronounced inflammation of the auditory canal, itching and peeling, and purulent exudate. Use up to 10 days.

Maximum Dosage (Ear Drops): Up to 5 drops in each auditory canal 4 times a day for no more than 5 days in a row for severe forms of external otitis with a purulent component. Use strictly under specialist supervision.

Preventive Dosage (Ear Drops): 2 drops in each auditory canal once a day in the evening for a tendency to eczema of the external ear, frequent external otitis, and during the season of high humidity. Preventive course — 5 days, repeat every 2 months.

Pediatric Dosage (Ear Drops): Use is permitted from 12 years of age. Dosage — 1–2 drops 1–2 times a day. In children under 12 years, safety has not been confirmed; use is not recommended.

Contraindications (Ear Drops): Perforation of the tympanic membrane, acute purulent otitis media, presence of foreign bodies in the auditory canal, allergy to components. During pregnancy and lactation — safety has not been confirmed.

Side Effects (Ear Drops): Local burning, mild itching, transient hearing loss due to the oil film. In case of overdose — irritation of the auricle skin, increased itching.

Adjustment for Patient Body Weight: Correction is not required since it is applied locally. In case of pronounced thinness and sensitive skin, a reduction in volume to 1–2 drops is possible.

Preparation Method (Ear Drops): Composition per 100 milliliters: dry root of barberry — 10 grams, organic coconut oil — 100 milliliters. Grind the root to 1–2 mm, keep in coconut oil in a water bath at 50 °C for 4 hours. After infusion, filter through gauze. If necessary, add 1 gram of beeswax for consistency. Pour into sterile dropper bottles.

Storage Conditions and Shelf Life (Ear Drops): Store in the refrigerator at a temperature of 4–8 °C, in a tightly closed dark glass bottle. Protect from light and electromagnetic radiation. Shelf life — 3 months. After opening — use within 14 days.

Cream — Berberis aristata

Indications (Cream): Plaque psoriasis, microbial eczema, localized neurodermatitis, seborrheic dermatitis, moderate acne, cutaneous candidiasis, cutaneous leishmaniasis, skin manifestations in hepatitis C, skin itching in cholestasis, skin metastases (as part of adjuvant therapy).

Standard Dosage (Cream): Apply a thin layer to the affected skin areas 2 times a day — morning and evening. Course — 14 days.

Enhanced Dosage (Cream): Apply 3 times a day for pronounced inflammation, hyperemia, peeling, and itching. Use up to 21 days.

Maximum Dosage (Cream): Up to 4 applications per day is possible short-term (no more than 5 days) for exacerbation of psoriasis, acute forms of neurodermatitis, and cutaneous leishmaniasis. Use requires medical supervision when the lesion area exceeds 10% of the body surface.

Preventive Dosage (Cream): 1 application per day at night for seasonal recurrences of eczema, psoriasis, dermatitis, and dry skin in the elderly. Preventive course — 10 days, every 2 months.

Pediatric Dosage (Cream): Permitted from 6 years of age. Apply once a day in a thin layer to a limited area (no more than 5×5 cm). Safety in children under 6 years has not been confirmed.

Contraindications (Cream): Deep skin wounds, weeping forms of dermatoses, individual intolerance to components. During pregnancy and lactation — permitted only for local limited use.

Side Effects (Cream): Burning, hyperemia, peeling, contact dermatitis. In case of overdose — maceration, increased itching and irritation.

Adjustment for Patient Body Weight: Correction is not required. In persons with body weight less than 45 kilograms, the application area should be limited to 5–10% of the skin surface.

Preparation Method (Cream): Composition per 100 grams: dry extract of barberry — 2 grams, organic coconut oil — 20 grams, distilled water — 60 grams, natural emulsifier (beeswax) — 10 grams, vegetable glycerin — 5 grams, natural vitamin E — 0.5 grams. Melt coconut oil and wax in a water bath, add dry extract, glycerin, and vitamin E. Separately heat water to 45 °C. Gradually combine the aqueous phase with the oil phase, stirring intensively until an emulsion is obtained. Cool to 30 °C and pour into jars.

Storage Conditions and Shelf Life (Cream): Store in a tightly closed dark glass or pharmaceutical plastic container at a temperature of 4–8 °C. Avoid exposure to direct light and EMI. Shelf life — 3 months. After opening, use within 21 days.

Ointment — Berberis aristata

Indications (Ointment): Plaque psoriasis, microbial eczema, seborrheic dermatitis, localized neurodermatitis, cutaneous leishmaniasis, candidiasis of skin folds, trophic ulcer of the lower extremities, skin itching due to bile outflow disorders, skin metastases in the infiltration stage, skin lesions in oncological liver diseases (as part of adjuvant therapy).

Standard Dosage (Ointment): Apply a thin layer to the affected areas 1–2 times a day. Duration of use — 10–14 days.

Enhanced Dosage (Ointment): 3 times a day for actively inflamed areas, foci of peeling and itching, including chronic psoriasis. Duration — up to 21 days.

Maximum Dosage (Ointment): 4 times a day, locally, no more than on 10% of the skin surface, up to 5 days in a row for acute inflammations, skin manifestations of malignant tumors, and leishmaniasis. Thereafter — only under medical supervision.

Preventive Dosage (Ointment): Once a day in the evening for recurrent eczema, psoriasis, and dermatitis against the background of bile stasis. Preventive course — 10 days, repeat every 2–3 months.

Pediatric Dosage (Ointment): From 6 years — once a day on limited skin areas (up to 3×3 cm). Safety in children under 6 years has not been confirmed; use is not recommended.

Contraindications (Ointment): Fresh skin wounds, weeping forms of dermatoses, individual hypersensitivity to ingredients. Safety data during pregnancy and lactation are absent; limited local use is recommended.

Side Effects (Ointment): Local reactions are possible: irritation, itching, contact dermatitis. In case of overdose — skin maceration, hyperemia, increased peeling.

Adjustment for Patient Body Weight: Dose adjustment is not required. For patients with body weight less than 50 kilograms — limit the application area. For weights above 90 kilograms, an increase in application frequency to 3 times is possible with good skin response.

Preparation Method (Ointment): For 100 grams: dry extract of barberry — 3 grams, organic coconut oil — 30 grams, lanolin — 30 grams, beeswax — 30 grams, natural vitamin E — 0.5 grams. Melt coconut oil, lanolin, and wax in a water bath at 50 °C. Introduce the extract, mix thoroughly. Add vitamin E when cooling to 35 °C. Pour into sterile jars.

Storage Conditions and Shelf Life (Ointment): Store in a tightly closed dark glass container at a temperature of 4–8 °C. Avoid light and EMI. Shelf life — up to 4 months. After opening — use within 21 days.

Cosmetic Product — Berberis aristata

Indications (Cosmetic Product): Skin hyperpigmentation, papulopustular acne, post-acne, skin photoaging, menopausal skin dryness, facial telangiectasia, skin manifestations in metabolic syndrome, oily seborrhea, tendency to acne in adolescents and adults, impaired facial skin microcirculation.

Standard Dosage (Cosmetic Product): Apply to pre-cleansed facial or body skin once a day, preferably in the evening. For acne and oily seborrhea — 2 times a day, morning and evening. Course — 21 days.

Enhanced Dosage (Cosmetic Product): Use 3 times a day (morning, afternoon, evening) on areas of local inflammation, pigmentation, post-acne, as well as for pronounced dryness and age-related skin changes. Course — up to 28 days.

Maximum Dosage (Cosmetic Product): Up to 4 applications per day locally (only on problem areas), no more than 7 days. Used for intense skin changes, acne in the exacerbation stage, and pigment spots against the background of inflammation. Should be combined with dermatologist monitoring.

Preventive Dosage (Cosmetic Product): 1 application per day in the evening for 10 days every 2 months for a tendency to acne, pigmentation, sensitive skin during hormonal instability, and in perimenopausal women. Course use in autumn and spring is possible.

Pediatric Dosage (Cosmetic Product): Use is permitted from 12 years of age — once a day on areas with acne or oily seborrhea. In children under 12 years — not recommended due to the lack of scientific data.

Contraindications (Cosmetic Product): Individual intolerance to components, open skin injuries, acute purulent inflammations. During pregnancy and lactation, local use on limited areas is permitted after specialist consultation.

Side Effects (Cosmetic Product): Transient redness, tingling, sensation of dryness. When exceeding the frequency of application — peeling, irritation, contact dermatitis.

Adjustment for Patient Body Weight: Correction is not required. In case of increased skin sensitivity in persons with body weight below 50 kilograms — start with 1 application every 2 days.

Preparation Method (Cosmetic Product): For 100 grams: dry extract of barberry — 2 grams, witch hazel hydrolate — 60 grams, organic coconut oil — 15 grams, plant-based emulsifier — 10 grams, vegetable glycerin — 10 grams, lavender essential oil — 3 drops. Heat coconut oil, emulsifier, and extract to 45 °C. Heat the aqueous phase (hydrolate and glycerin) to the same temperature. Mix the phases with active stirring, cool, add essential oil. Pour into cream or serum containers.

Storage Conditions and Shelf Life (Cosmetic Product): Store in the refrigerator at a temperature of 4–8 °C, in an airtight cosmetic package, without access to light. Shelf life — 90 days. After opening, use within 30 days.

Toxicity and Biosafety of Berberis aristata

The acute toxicity of Berberis aristata has been studied with respect to the main active alkaloid — berberine, as well as root extracts. According to preclinical studies, the LD₅₀ value for the dry extract of Berberis aristata in rats with oral administration is 2,600 mg/kg of body weight, which indicates low acute toxicity. When used in therapeutic dosages, no lethal effects are observed, and at doses above 1,000 mg/kg, only minor reversible digestive disturbances were recorded.

Berberine in high doses may have a cytotoxic effect, but at the same time demonstrates selectivity towards tumor cells. Chronic toxicological studies have shown the absence of a cumulative toxic effect with long-term use at doses up to 300 mg/kg. No mutagenicity, teratogenicity, or carcinogenicity was detected when using standardized extracts.

Berberis aristata is considered pharmacologically safe when therapeutic limits are observed, but requires caution in pregnant women and young children, due to insufficient research on reproductive toxicity.

Reference: https://www.ncbi.nlm.nih.gov/p...

Pharmacodynamics — Berberis aristata

The pharmacodynamic properties of Berberis aristata are determined primarily by the alkaloid berberine, as well as isoquinoline compounds such as berbamine, palmatine, jatrorrhizine, and columbamine. Based on biochemical and pharmacological studies, it has been established that the active components of the plant exhibit multi-level action, including systemic and local effects on physiological regulatory cascades.

The main mechanism of action of berberine is associated with its ability to interact with intracellular signaling pathways, including AMPK (adenosine monophosphate-activated protein kinase), MAPK (mitogen-activated protein kinase), and NF-κB (nuclear factor kappa-bi). Through modulation of these cascades, anti-inflammatory, antioxidant, and cytostatic effects are realized. Suppression of the expression of pro-inflammatory cytokines and mediators such as TNF-α, IL-6, and COX-2 has also been established, confirming activity at the level of the immune system.

From the gastrointestinal tract, inhibition of hydrochloric acid secretion, modulation of motility, and increased bile synthesis due to stimulation of the choleretic function of the liver are observed. Berberine also affects enterocyte channels, in particular chloride and sodium transporters, regulating water-salt balance and osmotic pressure in the intestinal lumen. Such action is accompanied by local antimicrobial activity due to intercalation of berberine into the DNA of bacterial cells and inhibition of topoisomerases.

In the immune system, berberine and related alkaloids contribute to the restoration of cellular immunity, stimulating the phagocytic activity of macrophages and inhibiting the activation of pathogenic Th17 cells. A decrease in oxidative stress at the cell membrane level, a reduction in the production of reactive oxygen species, and an increase in the activity of antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase) are observed. These mechanisms are mediated both by direct binding to intracellular targets and by regulation of the transcription of antioxidant genes.

From the perspective of the endocrine system, berberine is able to regulate the sensitivity of insulin receptors and reduce the activity of gluconeogenesis in the liver. Its ability to reduce the expression of PPAR-γ and enhance the translocation of GLUT-4 in muscle and adipose tissue has been established. Such effects are mediated both by direct action on receptor proteins and by secondary influence on the intestinal microbiota.

In the nervous system, Berberis aristata realizes a moderate sedative and anxiolytic potential through inhibition of monoamine oxidase A and B activity, as well as by increasing the levels of dopamine, serotonin, and gamma-aminobutyric acid (GABA) in the synaptic cleft. These effects demonstrate an influence on central neurotransmitter systems and can be realized both with systemic and local use.

Pharmacological studies also confirm the effect of berberine on angiogenesis, especially under conditions of proliferative activity of vascular endothelium. By suppressing VEGF-induced expression and inhibiting PI3K/Akt mechanisms, it is able to disrupt the growth of new vessels, which supports its anti-angiogenic properties.

Thus, the pharmacodynamics of Berberis aristata includes multicomponent regulation of metabolic, immune, inflammatory, neurotransmitter, and vascular processes. The action of the plant relies on specific intracellular targets and enzyme systems, confirmed by experimental and clinical studies.

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332327
https://pubmed.ncbi.nlm.nih.gov/16008210
https://link.springer.com/article/10.1007/s11418-020-01382-6
https://www.sciencedirect.com/science/article/pii/S0753332220303603

Pharmacokinetics — Berberis aristata

The pharmacokinetic characteristics of Berberis aristata are determined by the structure of its constituent biologically active compounds, mainly of alkaloid nature. The main route of administration when using powder, dry extract, or alcohol tincture is oral, while ointments, creams, suppositories, and oil infusions provide transdermal and transmucosal absorption.

With oral administration, the absorption of alkaloids begins in the small intestine. However, their bioavailability may be limited by the first-pass effect through the liver, which is explained by the active participation of liver microsomal enzymes and metabolic conversion into sulfo- and glucuronide conjugates. It has been established that with oral administration of Berberis aristata extracts, metabolites undergo reverse enterohepatic circulation, which contributes to prolonged action and partial cumulation with long-term use.

The distribution of alkaloids in the body is systemic in nature, with predominant accumulation in the tissues of the liver, intestines, spleen, and, partially, in mucous membranes. With transdermal application through creams and ointments, penetration is limited to the superficial layers of the skin, but may increase when the epidermal barrier is disrupted. With rectal and vaginal administration, the absorption of active substances occurs through the rich capillary network of the mucosa, bypassing the portal vein system, which allows reducing the burden on the liver and increasing systemic exposure.

The metabolism of Berberis aristata compounds is carried out primarily in the liver with the participation of cytochrome P450 enzymes, as well as in intestinal cells, where active substances can interact with the microflora. The ability of some alkaloids to influence the intestinal microbiome has been proven, including through inhibition of the growth of conditionally pathogenic strains and modulation of the local inflammatory response.

Excretion of metabolites occurs mainly with bile and to a lesser extent with urine. A small amount may be eliminated through the intestine unchanged. With local use, excretion occurs slowly, through the lymphatic system and skin, as well as with surface metabolites of sebum. With repeated use, accumulation in tissues with high lipid content, such as the liver and adipose tissue, cannot be ruled out.

Thus, the pharmacokinetic profile of Berberis aristata is due to the multi-stage transformation of alkaloid structures in the liver and intestines, the active participation of mucous membranes and skin with local administration, as well as possible modulation of the microbiota, which affects the overall pharmacological activity and duration of action.

References:
https://www.ncbi.nlm.nih.gov/p...
https://www.sciencedirect.com/...
https://pubmed.ncbi.nlm.nih.go...
https://link.springer.com/arti...

Mechanisms of Action and Scientific Rationale — Berberis aristata

The bio-pharmacological activity of Berberis aristata is primarily due to the presence of isoquinoline alkaloids — berberine, berbamine, palmatine, and jatrorrhizine, which have a confirmed ability to interact with multiple molecular targets in mammalian cells. The central mechanism of action of berberine is realized through inhibition of the NF-κB signaling cascade, accompanied by suppression of the transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, as well as the enzymes COX-2 and iNOS. This causes pronounced modulating effects on the activation of macrophages and neutrophils, as well as a decrease in the expression of adhesion molecules on the vascular endothelium.

At the level of intracellular energy and metabolic processes, berberine activates the enzyme AMP-activated protein kinase (AMPK), which regulates fatty acid catabolism, glucose metabolism, and mitochondrial biogenesis. Through this pathway, the modulation of metabolic and adaptive reactions in hepatocytes, adipocytes, and myocytes is carried out. Berberine also affects the expression of glucose transporters (GLUT4), reducing insulin resistance at the level of target tissues. Along with this, inhibition of the activation of the PI3K/Akt/mTOR cascade is observed, which is associated with the control of cell proliferation and pro-apoptotic effects.

Pharmacological studies have shown that Berberis aristata alkaloids interact with the hepatic cytochrome system, including CYP3A4 and CYP2D6, affecting the enzymatic transformation of xenobiotics and endogenous substrates. In addition, the ability of berberine to inhibit acetylcholinesterase (AChE) and monoamine oxidase (MAO-A/B) has been identified, which determines its moderate neuromodulating and anxiolytic effect at the level of the central nervous system. Indirectly, this leads to stabilization of the levels of serotonin, dopamine, and GABA in the synaptic cleft.

Regarding epithelial barriers, berberine is able to restore the structure of intercellular contacts, including tight junctions, and reduce the permeability of mucous membranes, which is associated with its effect on the expression of claudins and occludins. This effect has been confirmed in models of inflammatory lesions of the gastrointestinal mucosa. The antimicrobial effect is realized through intercalation into the DNA of bacterial cells and inhibition of topoisomerase activity, disrupting the processes of replication and transcription in microorganisms. Suppression of the activity of a number of gram-positive and gram-negative bacteria, as well as pathogenic fungi of the genus Candida, has been confirmed.

Additionally, Berberis aristata demonstrates anti-angiogenic properties, realized through a decrease in the expression of vascular endothelial growth factor (VEGF) and its receptors, as well as suppression of the activation of the JAK/STAT signaling pathway. This leads to inhibition of neovascularization and migration of endothelial cells, which is important in the context of regulation of vascular proliferation. At the level of the skin and mucous membranes, plant alkaloids reduce the expression of MMP-9 and MMP-2, preventing the destruction of the extracellular matrix and reducing the chronicity of inflammation.

Thus, the mechanisms of action of Berberis aristata are multi-level, covering cellular, enzymatic, and receptor targets. Their activity is documented in pharmacological studies and confirmed both at the molecular and tissue levels.

References:
https://www.ncbi.nlm.nih.gov/p...
https://pubmed.ncbi.nlm.nih.go...
https://www.sciencedirect.com/...
https://link.springer.com/arti...

Synergy — Berberis aristata

The pharmacological synergy of Berberis aristata with other natural and biologically active substances has been confirmed both at the level of preclinical models and in clinical observations. The key synergistic agent is curcumin, with which potentiation of anti-inflammatory and antiproliferative effects has been established due to the combined inhibition of the NF-κB signaling cascade, enhancement of the antioxidant response, and reduction of the expression of pro-inflammatory cytokines (*IL-6, TNF-α, IL-1β*). It has been proven that curcumin increases cellular permeability to berberine, thereby increasing its intracellular concentration and effectiveness.

Additional synergy is observed when combining Berberis aristata with resveratrol. This interaction has a modulating and protective nature, including enhancement of the activity of antioxidant defense enzymes (superoxide dismutase, catalase) and inhibition of the JAK/STAT cascade. The combined effect contributes to the regulation of the cell cycle and suppression of excessive angiogenesis. Such a combination has a tissue-specific effect on vascular and connective tissue regulation.

A potentiating interaction of Berberis aristata with green tea (Camellia sinensis) has also been established, due to the cumulative effect of flavonoids and alkaloids on the mechanisms of suppression of oxidative stress, inhibition of COX-2 activity, and stabilization of immune system cell membranes. Such synergy is realized to a greater extent at the systemic level, affecting metabolic and immune regulatory circuits.

An additive effect has been described in combination with Ginkgo biloba, which has been confirmed in neuroprotection models. The combined inhibition of monoamine oxidase (MAO-A/B) and the reduction of reactive oxygen species production in brain tissue determine the enhancement of the modulating effect on neurotransmitter systems. The interaction mechanism consists of a complex effect on the balance of mediators — dopamine, norepinephrine, and serotonin — as well as a reduction in neuroinflammatory activity.

Significant biochemical synergy has been identified when combining Berberis aristata with phytocompounds of licorice (Glycyrrhiza glabra), mainly due to glycyrrhizin and liquiritigenin. The combined effect has an enhancing effect on macrophage activity and suppression of virus-induced interleukin-8 expression. This combination is characterized by immunomodulating and barrier-protective effects, realized both at the cellular and mucosal levels.

A modulating and stabilizing effect has also been recorded with the simultaneous use of zinc and seleno-organic compounds, which is associated with the participation of berberine in the regulation of the transcription of antioxidant genes (Nrf2), as well as in the protection of DNA from oxidative damage. These interactions unfold primarily at the systemic level under conditions of oxidative stress and metabolic destabilization.

Thus, the synergistic interactions of Berberis aristata cover a wide range of pharmacological directions — from antioxidant and anti-inflammatory activity to immunomodulation, neuroprotection, and tissue-specific stabilization. The combined use with biologically active substances enhances the physiological effect, reduces the dose load, and can minimize side effects.

References:
https://www.ncbi.nlm.nih.gov/p...
https://pubmed.ncbi.nlm.nih.go...
https://www.sciencedirect.com/...
https://link.springer.com/arti...
https://pubmed.ncbi.nlm.nih.go...

Geography of Use and Traditional Medicine — Berberis aristata

Berberis aristata is traditionally used in South Asia, primarily in India, Nepal, Pakistan, Bangladesh, and Sri Lanka. Its ethnobotanical significance is especially great in Ayurvedic medicine, where the plant is known as Daruharidra and is included in numerous ancient formulations. The use of the root and bark of Berberis aristata is recorded in texts dating no later than the 1st millennium AD, in particular in the treatises "Charaka Samhita" and "Sushruta Samhita." In the tradition of Nepal, the plant is used by the Newar and Gurung peoples as a universal cleansing remedy, including in a ritual context.

In Tibetan medicine, Berberis aristata was included in collections known as "yellow preparations" (in some sources referred to as shing khur), where the plant was considered to balance bile and phlegm, and was used not only in oral forms but also in the form of wraps, rubbings, and smoking powders. In Tibetan monastic treatment, yellow decoctions with barberry root were used to purify the blood and restore energetic harmony. In Ladakhi culture, the root was considered a plant of strength, strengthening the spirit and purifying the body.

In northwestern India, particularly in the states of Himachal Pradesh and Uttarakhand, the roots and bark of Berberis aristata were used in village folk healing as a base for decoctions and concentrated ointments that were applied to the skin, rubbed into joints, and used for wound washing. Local tribal communities, such as the Gujjars and Bihar Musahars, used root decoction in ritual practice — in particular, for "purification of the spirit" before important ceremonies or childbirth.

In the southern and eastern parts of Pakistan, the plant is known as Sumbul-ut-teeb and was used in Greco-Arabic medicine systems (Unani) as part of multicomponent tinctures and powders. In this tradition, barberry was identified with a "cooling" and "drying" element and was included in ritual cleansing mixtures used before fasting or repentance.

In the culture of the peoples of Afghanistan, especially in the mountainous regions of the Hindu Kush, barberry root was used as a talisman; its pieces were kept in pouches and hung around the neck as protection from the evil eye and diseases. During the change of seasons, men rubbed their chests with root powder diluted in oil, believing that this strengthened the body before winter hardships.

In some regions of Western China (including Tibetan and Uyghur autonomous districts), Berberis aristata was used as part of semi-sacral ointments for protection from the "influence of wind" — one of the concepts of traditional Chinese medicine associated with sharp changes in physiology and psycho-emotional state. In the same areas, rituals are recorded in which barberry root was burned during prayer ceremonies in combination with juniper and cedar.

In Central Asia and the Caucasus, Berberis aristata is not a native plant; however, ethnic groups practicing Muslim phytotherapy used imported dry root in healing formulations. In some Sufi rituals of the 19th–20th centuries, it is mentioned as a "yellow root for the body and shadow," which likely indicates its cleansing and balancing significance.

Thus, Berberis aristata occupies a stable place in the medical and ritual traditions of South and Central Asia, as well as in Tibeto-Burman and Unani-Greek ethnophytoformulas, where its use has both therapeutic and sacred significance.